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BY-NC-ND license (http://creativecoSummary Background: Bariatric surgery (BS) is totally different from diabetes surgery (DS) in
the patient characters, goals of surgery, and management although similar in surgical proce-
dure. Comparison of BS and DS with long-term data is lacking.
Materials and methods: A retrospective review of patients who received BS and patients who
received DS at Min-Sheng General Hospital from 2007 to 2013 was designed. All inpatient and
outpatient follow-up data were analyzed. Patients undergoing BS for the treatment of morbid
obesity were compared with patients undergoing metabolic surgery for the treatment of type 2
diabetes mellitus (T2DM). Patients who received revision surgeries were excluded. The main
outcome measures were: (1) operation risk; (2) weight loss; and (3) diabetes remission.
Results: Between 2007 and 2013, 2073 patients who received BS and 741 patients who received
DS were recruited from both centers. DS patients were older (41.1  10.9 years vs. 33.1  9.3
years, p < 0.05) and were more likely to be male (40.2% vs. 28.2%, p < 0.05) and to have dia-
betes (100% vs. 6.0%, p < 0.05), however, they had similar body mass index (BMI) (37.9  8.0
vs. 38.5  9.7, p Z 0.78) compared to the BS patients. Surgical procedures are significantly
different between the two groups (73.3% of the DS surgeries were gastric bypass procedure,
whereas this procedure made up only 47.1% of BS surgeries). Although the major complication
rates were similar (2.0% vs. 2.4%), the DS program had a significant higher mortality rate than
the BS program (0.54% vs. 0.1%; p < 0.05). At the 5-year follow-up time point, 58.0% of the BS
patients had achieved successful results (weight loss > 30%) and 80% of the DS patients had
complete remission of their diabetes [hemoglobin A1c (HbA1c) < 6.0%]. Both the DS and the
BS group had good results in up to 85% of the patients at the 5-year follow-up time point.ng authors declare no conflicts of interest.
, Chin Kuo Road, Min-Sheng General Hospital, Tauoyan, Taiwan.
@yahoo.com.tw (W.-J. Lee).
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Bariatric versus diabetes surgery 97Conclusion: The clinical profiles were very different between the BS and the DS programs. Both
programs achieved the desired outcomes equally well, however, the DS program had a higher
risk than the BS program.
Copyright ª 2015, Asian Surgical Association. Published by Elsevier Taiwan LLC. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).1. Introduction
Obesity and type 2 diabetes mellitus (T2DM) are becoming
epidemic diseases worldwide.1,2 These two diseases are
closely related and are both very difficult to treat.3,4 Bar-
iatric surgery (BS), aimed at weight reduction, has been
proven to be a viable option for the treatment of severe
obesity in comparison to conservative methods, resulting in
long-lasting weight loss, improved quality-of-life, and the
resolution of obesity-related comorbidities.5 Among all of the
obesity-related comorbidities, BS has been proven especially
successful in treating T2DM6e8 in morbidly obese patients
[body mass index (BMI) > 35 kg/m2] as well as preventing the
development of T2DM.9 Recently, gastrointestinal metabolic
surgery has been proposed as a new treatment modality for
T2DM in patients with BMI < 35 l g/m2.10 Several randomized
trials have proven that metabolic surgery resulted in better
glycemic control compared with medical treatment in T2DM
patients with BMI < 35 kg/m2.11e17
We started our metabolic surgery program in 2007. An
independent diabetes surgery (DS) center was set up in
addition to the original BS center, because we realized that
the patient characters, goals of surgery, and management
are totally different. The two programs were different in
their stated goals and were managed by different case
coordinators, but offered similar procedures from the same
surgeons. In this study, we sought to compare the charac-
teristics of the patient populations, perioperative out-
comes, and long-term effects of these two programs.
2. Materials and methods
2.1. Setting
We began performing BS in 1997 and began performing
laparoscopic BS in 1998.18 We launched our BS center in
2004. This center hosted our BS program and a multidisci-
plinary team was involved. The program was managed by a
coordinator (Tsou JJ), and the patients were followed by
surgeons with the consultation of the multidisciplinary
team if necessary. An independent DS center was estab-
lished in 2007 when we realized that patients requiring
T2DM treatment had totally different clinical profiles and
goals of surgery compared with the bariatric patients. The
clinical management of the diabetic surgical patients is also
totally different from that of the bariatric patients. This
center is led by an endocrinologist (Chong K) and managed
by a coordinator (Chen SC). The diabetic patients were
managed by a multidisciplinary team, and each patient was
followed by an endocrinologist. The two programs weredifferent in their stated goals and were managed by
different case coordinators, but offered similar procedures
from the same group of surgeons (Lee WJ, Ser KH, Chen
RC). Between 2007 and 2013, the 2073 patients who
received BS and the 741 who received the DS were
recruited from both centers. Patients who received revision
surgeries were excluded. The demographics, operative
time, length of stay, weight loss, and the effects on
comorbidities and mortality were evaluated.
The study was conducted in Min-Sheng General Hospital
of the National Taiwan University and was approved by the
human research review board at Min-Sheng General Hospi-
tal. All of the clinical data were prospectively collected and
stored in a personal computer data base.
2.2. Surgery
The surgical team performed various types of surgical pro-
cedures and had broad experience with bariatric/metabolic
surgeries. The performed surgical procedures included three
types of gastric bypass procedures: laparoscopic Roux-en-Y
gastric bypass (LRYGB), laparoscopic mini gastric bypass
(LMGB), and single anastomosis duodenojejunal bypass with
sleeve gastrectomy (SADJB-SG), which have been published
previously.19,20 In brief, using a standard five-port laparo-
scopic technique, LRYGB was performed by the antecolic
and antegastric route with 100 cm of biliopancreatic limb
and 100e200 cm of alimentary limb. The gastric pouch was
approximately 20 mL and the gastrojejunostomy was
created by a stapler technique with an anastomosis 1.2 cm
diameter wide. LMGB was performed first by creating a long
sleeved gastric tube approximately 2.0 cm wide along the
lesser curvature from the antrum to the angle of His. Then,
a Billroth II type loop gastroenterostomy was created with
the intestine at 150e250 cm distal to the ligament of Trietz.
SADJB-SG was performed first by creating a sleeve gastrec-
tomy over a 36Fr bougie and leaving a 4 cm long antrum.
Then, the duodenum was transected 4 cm distal to the py-
loric ring and a loop duodenojejunostomy was created with
the intestine at 150e250 cm distal to the ligament of Treitz.
Other procedures included the laparoscopic adjustable
gastric banding (LAGB) and the laparoscopic sleeve gas-
trectomy (LSG).21,22 The type of operation performed is
usually codecided by the patient themselves and the sur-
geon after several comprehensive seminars with the multi-
disciplinary team.
2.3. Patients and outcome measures
Patient follow up was scheduled at the 1st, 3rd, 6th, and 12th
month for the 1st year and then annually. Body weight loss
Table 1 The clinical characteristics of bariatric and dia-
betes patients prior to bariatric/metabolic surgery.
Bariatric
(n Z 2073)
Diabetes
(n Z 741)
P
Age (y) 33.1  9.3 41.1  10.9 <0.001
Sex (female) 1529 (73.8) 443 (59.8) <0.001
Body weight (kg) 105.2  26.3 103.9  25.4 0.245
Body height (cm) 165.4  31.9 165.2  8.4 0.879
BMI (kg/m2) 38.5  7.9 37.9  8.0 0.780
Waist circumference
(cm)
116.2  44.2 115.7  18.1 0.805
Uric acid (mg/dL) 6.9  1.8 6.6  1.9 <0.001
Hypertension 1063 (51.3) 450 (60.7) < 0.001
Dyslipidemia 968 (46.7) 357 (48.2) 0.531
AST (U/L) 28.9  31.5 37.2  30.4 <0.001
Albumin (mg/dL) 4.5  1.9 4.4  0.3 0.224
WBC (103/uL) 9.5  10.3 8.4  2.3 <0.001
Creatinine (mg/dL) 0.7  0.2 0.8  0.3 <0.001
Patients with T2DM 125 (6.0) 741 (100) <0.001
Duration of T2DM (y) 0.1  0.3 3.9  4.6 <0.001
HbA1c (%) 5.8  0.7 8.4  2.9 <0.001
Glucose (mg/dL) 94.0  17.8 162.1  68.9 <0.001
Insulin usage (case) 5 (4.0) 126 (17.0) <0.001
Data are presented as mean  standard deviation or n (%).
AST Z aspartate aminotransferase; BMI Z body mass index;
HbA1c Z hemoglobin A1c; T2DM Z type 2 diabetes;
WBC Z white blood cell.
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recorded during every visit. The success of BS was defined
as very successful (weight loss > 30%) and successful
(weight loss > 20% but < 30%). The success of DS was
defined as very successful [complete remission of T2DM,
hemoglobin A1c (HbA1c) < 6%] and successful (partial
remission of T2DM, HbA1c < 6.5%).23 Patients were also
asked to grade their satisfaction with the surgery at the
annual visits. The classification was divided into five grades
ranging from excellent to poor.
All patients received a quality-of-life questionnaire
evaluation at their preoperative assessments and post-
operative follow up. Quality-of-life was measured by the
Gastrointestinal Quality-of-Life Index (GIQLI), a 36-item
questionnaire.24 In the analysis, the results of the ques-
tionnaire were divided into four domains: symptoms
(19 items), physical status (7 items), psychological emo-
tions (6 items), and social functioning (4 items). Each item
was scored on a range from 0 to 4 (from the worst to the
best option). The maximum score was 144. This question-
naire had been verified in previous studies19,22,25e28 and the
normal range was from 118 to 125.28
Perioperative complications were defined using the
Clavien-Dindo classification for grading the severity of sur-
gical complications.29 Grade I (minor deterioration from the
normal postoperative course) and Grade II (complications
can be treated by drugs, blood transfusion, physiotherapy,
or nutritional support) are classified as minor complica-
tions. Grade III (complications require interventional or
operative treatment), and Grade IV (complications are life-
threatening complications with the need for intensive care
unit management) are classified as major complications.
Grade V is defined as mortality of the patient.2.4. Statistical analysis
All statistical analyses were performed using SPSS version
12.01 (SPSS Inc., Chicago, IL, USA), with a baseline com-
parison made using Chi-square tests and two-sample t tests.
Continuous variables were expressed as the mean (and
standard deviation). The differences in pertinent charac-
teristics were established using the t test for independent
samples. A two-sided p value Z 0.05 was considered sta-
tistically significant.3. Results3.1. Participants
Overall 2814 patients (2073 in the BS program and 741 in the
DS program) were evaluated. As shown in Table 1, the DS
patients were older (41.1  10.9 years vs. 33.1  9.3 years,
p < 0.001) and were more likely to be male (40.2% vs.
26.2%, p < 0.001) and to have diabetes (100% vs. 6.0%,
p < 0.001); however, they had BMI values similar to those of
the BS patients (37.9  8.0 vs. 38.5  7.9, p Z 0.78). The
DS patients also had a significantly higher prevalence of
hypertension.3.2. Surgical complications
Surgical procedures are significantly different between
the two groups (73.3% of the DS patients received gastric
bypass procedures whereas only 47.1% of the BS patients
received bypass surgery). The surgical time was signifi-
cantly longer for the DS patients (145.8  40.6 minutes vs.
131.7  39.1 minutes, p < 0.05). The DS patients also had
a greater intraoperative blood loss and a longer mean
hospital stay compared with the BS patients (Table 2). The
overall complication rate was higher in the DS program
than the BS program (10.5% vs. 7.4%), but the major
complication rate was similar between the two groups
(2.4% vs. 2.0%, p Z 0.07). Among 50 (2.4%) of the BS pa-
tients who had major complications; only two (0.1%) died,
while the other 48 recovered without severe sequelae.
One patient died of sleep apnea in the perioperative
period after an unsuccessful resuscitation. The other pa-
tient died of multiorgan failure after a complication of
internal bleeding, omentum infarction, and sepsis. Among
the 15 (2.0%) DS patients with major complications, four
(0.54%) died, and three (0.40%) had severe neurologic
sequelae due to vascular complications. One case died of
liver failure after prolonged treatment of a minor leakage
after gastric bypass. Two cases died of multiorgan failure
after delayed diagnosis of leakage after gastric bypass.
One case died of multiorgan failure after delayed
diagnosis of internal bleeding. Overall, the DS group
had a significantly higher surgical mortality and
complication with severe sequelae (0.94% vs. 0.1%;
p < 0.01).
Table 2 Comparison of surgical procedure and perioper-
ative parameters in patients undergoing bariatric versus
diabetes surgery.
Bariatric
(n Z 2073)
Diabetes
(n Z 741)
p
Procedure <0.001
LRYGB 472 (22.8) 257 (34.7)
LMGB 489 (23.6) 217 (29.3)
LSG 765 (36.9) 137 (18.5)
SADJB-SG 14 (0.7) 69 (9.3)
LAGB 128 (6.2) 20 (2.7%)
Mean operative time
(min)
131.7  39.1 145.8  40.6 <0.001
Intraoperative blood
loss (mL)
41.9  44.8 54.0  114.7 <0.001
Postoperative flatus
passage (d)
1.7  0.7 1.8  0.6 0.21
Postoperative hospital
stay (d)
3.3  1.7 4.2  1.7 <0.001
Early postoperative
complication
Minor 105 (5.0) 63 (8.5) 0.001
Major 50 (2.4) 15 (2.0) 0.547
Leakage 31 (1.5) 7 (1.0)
Bowel obstruction 3 (0.1) 1 (0.1)
Major bleeding 8 (0.4) 3 (0.4)
Hepatic failure 0 1 (0.1)
Renal failure 0 1 (0.1)
Stricture of
anastomosis
1 (0.05) 1 (0.1)
Respiratory failure 1 (0.05) 0
Heart failure 1 (0.05) 0
Mortality 2 (0.1) 4 (0.54) 0.017
Data are presented as mean  standard deviation or n (%).
LAGB: laparoscopic adjustable gastric banding; LMGB: laparo-
scopic mini gastric bypass; LRYGB: laparoscopic Roux-en-Y
gastric bypass; LSG: laparoscopic sleeve gastrectomy; SADJB-
SG: single anastomosis duodenojejunal bypass-sleeve
gastrectomy.
BMI = body mass index.
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Figure 1 Weight loss (%) after bariatric and
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Most of the patients were regularly followed at outpatient
clinics; some patients were referred to local hospitals or
clinics for further follow-up due to the long travel distance.
At follow-up, the BS patients had achieved superior weight
loss and a lower mean BMI compared with the DS patients at
the 5-year follow-up time point (Figure 1). At the 5-year
follow-up time point, a significant higher portion of the
BS patients had very successful weight loss compared with
the DS patients (58% vs. 33.9%, p < 0.05).
Complete remission of T2DM was achieved in 80% of the
DS patients at the 5-year follow-up time point (Table 3).
Another 9.2% of the DS patients achieved partial remission.
The mean HbA1c level decreased from a preoperative value
of 8.4  2.9% to 6.2  1.3 at the 5-year follow-up time
point.
3.4. Quality-of-life
The preoperative GIQLI scores were similar in the two
groups (Table 4). Five years after surgery, the mean GIQLI
score was significantly higher than the preoperative score
in both groups. Significantly higher subtotals were found in
the general quality-of-life assessment, including in the
domains of physical, social, and emotional function (Table
4). There was a significant decrease in the symptoms
score after surgery in both groups due to the postoperative
presence of gastrointestinal symptoms in both groups.
3.5. Patient satisfaction
At the 5-year follow-up time point, the patient’s satisfac-
tion was very high in both groups (Table 5). Up to 88% of the
patients had excellent or very good satisfaction with their
surgery, however, more patients in the BS group felt
excellent than in the DS group (53.2% vs. 29.4%, p < 0.05).
4. Discussion
This study confirmed that BS can be performed as a meta-
bolic surgery for the treatment of T2DM, and that BS0.0%
5.0%
10.0%
15.0%
20.0%
25.0%
30.0%
35.0%
4 y 5 y
Weight loss%
eight loss% DM Weight loss%
diabetes surgery. BMI Z body mass index.
Table 3 Comparison of clinical characteristics of patients
5 years after bariatric (BS) versus diabetes surgery (DS).
Variable BS
(n Z 450)
DS
(n Z 168)
p
BMI (kg/m2) 26.5  4.8 28.7  6.3 0.055
Excess body weight loss (%) 77.1  25.1 63.3  19.0 0.050
Total weight loss (%) 29.6  12.7 25.3  10.3 0.030
Great success (>30%) 261 (58.0) 57 (33.9) 0.017
Success (20e30%) 123 (27.3) 69 (41.1)
Partial success (<20%) 66 (14.7) 42 (25)
Remission of T2DM
Great success (HbA1c
<6.0%)
e 156 (80)
Success (HbA1c 6.0e6.5%) e 18 (9.2)
Partial success (HbA1c
>6.5%)
e 21 (10.8)
Data are presented as mean  standard deviation or n (%).
BMI Z body mass index; HbA1c Z hemoglobin A1c;
T2DM Z type 2 diabetes.
Table 5 Patient satisfaction with bariatric and diabetes
surgery at 5-year follow-up time point.
Bariatric
(n Z 470)
Diabetes
(n Z 86)
p
Excellent 247 (53.2) 26 (29.4) 0.206
Very good 172 (36.2) 50 (58.8)
Good 39 (8.5) 6 (5.9)
Fair 12 (2.1) 4 (5.9)
Worse 0 0
Data are presented as n (%).
100 W.-J. Lee et al.achieved very good glycemic control up to 5 years with very
high patient satisfaction. The result is consistent with the
recently reported results of laparoscopic BS.30,31 However,
although the major complication rate was similar between
the two groups, patients who received DS tended to
develop more severe complications that resulted in higher
mortality rates. This finding corroborated with a recent
report from Inabnet et al31 that BS carried a higher risk in
patients with metabolic syndrome compared with patients
without metabolic syndrome. The reason for the more se-
vere complication in the DS patients might be related to the
compromised cardiovascular system and depressed immu-
nity in patients with poorly controlled diabetes.32,33
In this study, the patient characteristics are significantly
different. Patients requesting diabetes treatment were
significantly older and had more comorbidities than pa-
tients requesting BS. These differences are reasonable and
in accordance with the previous report.34 Although the DS
patients were sicker than the BS patients, more patients in
the DS group received the more complicated gastric bypass
procedures. This is because excluding the duodenum in the
bypass procedure had been proven to be more effective in
glycemic control than a procedure without duodenum
exclusion, such as the LSG or the LAGB.5,8,12,13,17Table 4 Overall and individual domain scores of the gastrointe
postoperatively for patients undergoing bariatric and diabetes su
GIQLI Bariatric
(preoperative)
n Z 1401
Bariatric
(postoperative 5 ye
n Z 470
Overall 108.4  15.7 110.7  16.5 *
Symptoms 64.5  6.6 57.6  9.2 *
Physical 16.6  5.3 20.4  5.0*
Emotional 12.1  4.0 15.9  2.6*
Social 15.2  3.7 16.8  2.8*
*p < 0.05 compared with the preoperative data.Therefore, we only advised patients with high BMI, a
short duration of T2DM, and good B-cell preservation to
undergo an LSG procedure.35 By contrast, in patients
without T2DM, LSG is becoming the leading type of BS.
Recent studies have supported that LSG is a durable BS
comparable to gastric bypass procedures.36,37 The other
advantages of LSG include the avoidance of gastric cancer
risk in the excluded stomach and a reduction of the inci-
dence of micronutrient deficiency. These factors result in
the discordance of surgical procedures between the BS and
DS groups.
In DS, a novel procedure, SADJB-SG, has been developed
and is specifically designed for metabolic surgery.20 This
operation avoids the risk of remnant gastric cancer arising
from excluded stomach. By preserving the pylorus, this
operation may decrease the incidence of dumping syn-
drome and a hypoglycemic episode. A single loop anasto-
mosis also simplifies the operation and decreases the
surgical risks in this group of vulnerable patients. Currently,
approximately 30% of our diabetes surgeries use the SADJB-
SG procedure. We are continually investigating the long-
term efficacy and functional advantages of this novel
procedure.
In this study, patients with diabetes do lose less weight
than patients without diabetes. Starting with a similar BMI,
the BS group achieved a higher weight loss and a lower BMI
compared with the DS group 5 years after surgery. However,
although weight loss is inferior in the DS group, the remission
of diabetes remained high in the DS group, which highlights
the role of weight loss in diabetes treatment and the diffi-
culty of losing weight by medical treatment in this group of
patients. The selection of the proper patients to receive DS
is very important for the success of the DS. In our previous
study, BMI, duration of diabetes, and C-peptide levels arestinal quality-of-life index (GIQLI) preoperatively and 5 years
rgery.
ars)
Diabetes
(preoperative)
n Z 564
Diabetes
(postoperative 5 years)
n Z 86
109.3  18.5 116.0  14.4 *
64.3  8.5 59.6  9.0 *
17.2  5.5 22.5  3.5 *
12.8  3.9 16.1  3.1 *
15.0  4.3 17.9  2.2
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Together with age, an ABCD score had been proposed for
patient selection for DS.39 In our diabetic program, we not
only excluded patients with long-term disease and poor B-
cell preservation, we also limited patient age to <65 years.
Although DS can be considered a treatment option for
patients with poorly controlled diabetes despite the high
remission rate and patient’s satisfaction rate, safety is still
the first priority in DS. This group of patients is relatively
vulnerable, and may be subject to possible vascular com-
plications due to a long history of diabetes, especially in
patients with poorly controlled disease. In this study, we
performed a routine cardiac stress test for all of our pa-
tients. Some patients were found to have coronary artery
diseases and received stent treatment before proceeding
with the diabetes surgeries. We also intensively monitored
our patients within the first 24 hours with a low threshold
for laboratory and computer tomography study. Patients
with poorly controlled diabetes or other metabolic disor-
ders, such as extreme hyperlipidemia, were admitted 2
days before surgery and received a short-term intensive
treatment to optimize their medical condition prior to
surgery. In our experience, these policies reduce the risks
and improve the safety of DS.
In conclusion, this study is the first to report the out-
comes of DS compared with BS after 5 years of follow up.
The results support the application of bariatric/metabolic
surgery in diabetes treatment and highlight the importance
of different strategies for managing these two groups of
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